GlobalRPh Renal Dosing Masterv7.4
Renal Dosing Master: fast drug lookup
GlobalRPh source record

Rivaroxaban (Xarelto)

Read renal action and limits
Local official-label summarySource retrieved 2026-09-05See the evidence for this drug3 sources available - open source summaries, references and comparisons

Xarelto / Rivaroxaban

READ THE SOURCE-SPECIFIC ANSWER

Renal guidance at a glance

Cautions / source differences (1)

Use the renal measure and units named by this source. Confirm product, indication, age, stable versus changing kidney function, and exact dialysis modality. The selected summary is not a complete prescribing monograph. Renal method and dosing checklist

Choose a source to read (3)

Display order is not a clinical ranking. Date of retrieval is not the label revision date. Sources are never merged into one regimen. Other sources and conflicts remain below.

1 additional source qualifications - review before use
Xarelto - product and source limitations

Use the table for the specific indication. The AF, CAD/PAD and pediatric instructions have different eligibility and dosing assumptions.

Before applying: Apply only to the stated formulation, indication and renal population.

Also check: Xarelto - product and source limitations

Official source

Xarelto - labeled renal guidance

Renal action and limits

Rivaroxaban (Xarelto), adult oral DVT/PE treatment
Creatinine clearance (CrCl), mL/min

Action or finding
For adult DVT/PE treatment, avoid rivaroxaban if CrCl is below 15 mL/min. At 15 to below 30, evidence is limited and bleeding warrants close evaluation.
Limits and monitoring
Use the table for the specific indication. The AF, CAD/PAD and pediatric instructions have different eligibility and dosing assumptions.
Before use
Apply only to the stated formulation, indication and renal population.

DailyMed SPL version 65, posted Sep 11, 2026 | Selected sections checked 2026-11-07. Independent clinical review pending.

Choose a product and source Xarelto | GlobalRPh RX passage All evidence
Product / population
Rivaroxaban (Xarelto), adult oral DVT/PE treatment
Renal measure
Creatinine clearance (CrCl), mL/min
Source revision
DailyMed SPL version 65, posted Sep 11, 2026
Retrieved
2026-11-07 (not the revision date)
Restriction or avoidance guidance. Read the specific threshold, age, formulation and dialysis exclusions; do not generalize across products.

Renal guidance: 5.4 Use in Patients with Renal Impairment / 8.6 Renal Impairment

For adult DVT/PE treatment, avoid rivaroxaban if CrCl is below 15 mL/min. At 15 to below 30, evidence is limited and bleeding warrants close evaluation. Use the table for the specific indication. The AF, CAD/PAD and pediatric instructions have different eligibility and dosing assumptions.

Source revision: DailyMed SPL version 65, posted Sep 11, 2026 | Retrieved: 2026-11-07. Retrieval date is not the revision date.

Source: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10db92f9-2300-4a80-836b-673e1ae91610

Scope: Selected renal passages reviewed; independent clinician adjudication pending. GlobalRPh v7.4.

Full source card / provenance

All sources, comparison tools and evidence navigation
Added / rechecked in v7.4

Read source findings

Read source-specific summaries and their qualifications. Retrieval date is not label revision date. Recent review does not imply clinical approval.

Official

Xarelto - labeled renal guidance

Retrieved: 2026-11-07
Source revision: DailyMed SPL version 65, posted Sep 11, 2026

Renal measure: Creatinine clearance (CrCl), mL/min

Read this dated source finding
Rxlist

Xarelto - selected RX renal passage

Retrieved: 2026-11-07
Source revision: Mirror revision not established in the reviewed passage.

Renal measure: Use the renal measure explicitly present in the RX passage.

Read this dated source finding
See all retained evidence sources
Source-first renal review

Evidence sources and renal implications

Choose a source to jump directly to its locally stored result. Qualitative precautions and evidence gaps remain visible even when no numerical clearance schedule is supplied.

Read 1 source difference / applicability notes

Official product label

Xarelto - labeled renal guidance

Restriction or avoidance guidance. Read the specific threshold, age, formulation and dialysis exclusions; do not generalize across products.

Rivaroxaban (Xarelto), adult oral DVT/PE treatment

Renal method: Creatinine clearance (CrCl), mL/min
Retrieved: 2026-11-07

Read local renal resultOpen this source quick answerOpen original reference
GlobalRPh RX List

Xarelto - selected RX renal passage

Restriction or avoidance guidance. Read the specific threshold, age, formulation and dialysis exclusions; do not generalize across products.

Rivaroxaban (Xarelto), adult oral DVT/PE treatment

Renal method: Use the renal measure explicitly present in the RX passage.
Retrieved: 2026-11-07

Read local renal resultOpen this source quick answerOpen original reference

Source presence is not independent validation. A label mirror is not a second independent source; review the original reference and exact formulation.

Product / population check

Confirm the exact formulation before using a renal source

These links compare product identities, not interchangeable doses. A selected summary is not a complete prescribing monograph.

Source-specific review points

Xarelto - product and source limitations

Read the attributed comparison notes and source cards below. No conflict has been silently adjudicated.

Source-quality holds
Find text within this drug
Find a term without leaving this drug

Search the stored clinical text

Locate a word or phrase within this drug's source summaries. Choose all sources or one source to focus the search. The selection never hides warnings or source text, changes a dose, or proves that a renal finding is absent.

Find:

Enter at least two characters. This in-page search is processed in your browser. Do not enter patient identifiers; advertising scripts also run on this page.

All source summaries, original wording and provenance
Before applying a renal protocol

Check the setting. Compare whole sources.

No patient-specific dose is calculated. Context choices only display reminders; they do not validate, hide or change any regimen.

Share a reproducible source review

Choose sources below, then open a print-ready comparison with product scope, renal method, dates and cautions. Links can pin the exact local cards; they never contain patient values or choose a dose.

Open / share selected sources
Jump to renal guidanceRead 1 difference / caution notesClinician guide

Select two distinct source versions. The complete stored summaries will appear below.

Build a source-review outline for documentation

This creates a blank decision outline with the source identities you select, not a dose recommendation or completed clinical assessment. No patient fields are collected, saved or sent. Complete the clinical decisions in your approved documentation system.

Choose one or two sources above or use the source checkboxes below.

Renal-context checklist: population, kidney trend and dialysis

These prompts are a reading aid, not a prescription checklist or proof that all requirements have been met. No selections are stored or sent to a server.

Read the exact source scope, renal metric and date before selecting a row. No applicability assessment has been performed.

See source-specific renal methods and the clinical interpretation guide for the supporting context.

Read before choosing a regimen

Source differences and product cautions

Search differences across all drugs

These are specific issues found during source review, not an automated judgment that one source is universally correct. A label mirror and its original label are not independent evidence.

Source scope / renal recommendation differences

Xarelto - product and source limitations

Use the table for the specific indication. The AF, CAD/PAD and pediatric instructions have different eligibility and dosing assumptions.

How to use this: Apply only to the stated formulation, indication and renal population.

Xarelto - labeled renal guidanceXarelto - selected RX renal passage

Selected renal passages reviewed; independent clinician adjudication pending.

Go directly to the relevant source section

Renal dosing and precautions

Choose a source, then jump to its renal or dialysis section. These links locate stored text; they do not merge regimens or certify that sources agree.

Independent clinical review is pending. These selected summaries are not an approved institutional dosing protocol. Confirm the exact product, the complete current source and local policy before use.

No dialysis or renal heading shown? Read the complete source summary. Absence of a heading is not evidence that dose adjustment is unnecessary.

Compare or copy source versions

All content below is stored locally. Read a whole source version; do not combine its dose with another source's interval, renal metric or dialysis assumptions.

Original content / product scopeXarelto - labeled renal guidanceXarelto - selected RX renal passage
Choose two source checkboxes below.
Historical source content is not a current prescription. Original GlobalRPh recommendations are preserved, not automatically certified as current. Product-label and professional additions below are separately attributed. Confirm indication, population, kidney-function method, monitoring and the full prescribing information before applying a regimen.

Important source distinctions

Historical indication-specific renal thresholds and recurrence-prevention regimen are not represented as current Xarelto labeling. Current labeling must be reviewed separately.

Locally stored source content

Original GlobalRPh protocol

Clinical facts and comments transcribed into a structured reading format. Read the original source for its complete context: https://globalrph.com/renal/rivaroxaban-xarelto/

Original indications and adult dosing

Factor Xa inhibitor for nonvalvular atrial-fibrillation stroke/systemic-embolism prevention; DVT/PE treatment and recurrence prevention; and DVT prophylaxis after hip/knee replacement.

Take 15 and 20 mg tablets with food; 10 mg may be taken with or without food.

Nonvalvular AF: CrCl above 50 mL/min, 20 mg once daily with the evening meal; CrCl 15-50, 15 mg once daily with the evening meal.

Acute DVT/PE: 15 mg twice daily with food for 21 days, followed by 20 mg once daily with food. The historical source also gives 20 mg daily for long-term recurrence reduction.

Hip/knee-replacement prophylaxis: 10 mg once daily. The source lists 10, 15 and 20 mg tablets.

GRPH-rivaroxaban-xarelto-01 · Source section: Original indications and adult dosingRenal section finder

Renal Dosing and monitoring

Nonvalvular AF: avoid below CrCl 15; increased exposure is expected. Assess renal function periodically and more frequently when deterioration is possible. Discontinue if acute renal failure develops.

For DVT/PE treatment/recurrence prevention and hip/knee-replacement prophylaxis, this historical page says to avoid below CrCl 30 because of increased exposure/effect. For postoperative prophylaxis at CrCl 30-50, closely evaluate signs of blood loss. Discontinue for acute renal failure.

GRPH-rivaroxaban-xarelto-02 · Source section: Renal Dosing and monitoringRenal section finder

Hemodialysis

The original source says to avoid.

GRPH-rivaroxaban-xarelto-03 · Source section: HemodialysisRenal section finder
Separate U.S. product-label layer

FDA / DailyMed dosing and renal information

Official

Xarelto - labeled renal guidance

Open original reference

Open / share this exact local source

DailyMed / product prescribing information · Rivaroxaban (Xarelto), adult oral DVT/PE treatment

Renal method: Creatinine clearance (CrCl), mL/min
Source date: DailyMed SPL version 65, posted Sep 11, 2026
Retrieved: 2026-11-07

Restriction or avoidance guidance. Read the specific threshold, age, formulation and dialysis exclusions; do not generalize across products.

Selected renal passages reviewed; independent clinician adjudication pending.

Renal guidance: 5.4 Use in Patients with Renal Impairment / 8.6 Renal Impairment

For adult DVT/PE treatment, avoid rivaroxaban if CrCl is below 15 mL/min. At 15 to below 30, evidence is limited and bleeding warrants close evaluation. Use the table for the specific indication. The AF, CAD/PAD and pediatric instructions have different eligibility and dosing assumptions.

RDM74-xarelto-official-1 · Source locator: Renal guidance: 5.4 Use in Patients with Renal Impairment / 8.6 Renal Impairment

Source identity and provenance
Source family
product_label
Source
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10db92f9-2300-4a80-836b-673e1ae91610
Retrieved
2026-11-07
Renal-function method
Creatinine clearance (CrCl), mL/min
Source date/version
DailyMed SPL version 65, posted Sep 11, 2026
Hash meaning
SHA-256 of the local selected-source summary
Local summary SHA-256
3759c0cdc2001d44223e8980d30aee0c1ab5ac6259eb9e0a0e1dc71f9468225a
Locally imported selected renal sections

GlobalRPh RX List renal information

Rxlist

Xarelto - selected RX renal passage

Open original reference

Open / share this exact local source

GlobalRPh RX List / product-label mirror · Rivaroxaban (Xarelto), adult oral DVT/PE treatment

Renal method: Use the renal measure explicitly present in the RX passage.
Source date: Mirror revision not established in the reviewed passage.
Retrieved: 2026-11-07

Label mirror, not independent corroboration. This is selected locally stored RX List content. Full monograph import and current official-label review are not implied.
Restriction or avoidance guidance. Read the specific threshold, age, formulation and dialysis exclusions; do not generalize across products.

Selected renal passages reviewed; independent clinician adjudication pending.

RX List: selected renal passage

The RX renal warning identifies the below-15 CrCl restriction for the adult VTE indications.

RDM74-xarelto-rxlist-1 · Source locator: RX List: selected renal passage

Source-specific limits

This mirror and the underlying product label share a source family.

Source identity and provenance
Source family
product_label_mirror
Source
https://globalrph.com/rx-list/xarelto-drug/
Retrieved
2026-11-07
Renal-function method
Use the renal measure explicitly present in the RX passage.
Source date/version
Mirror revision not established in the reviewed passage.
Hash meaning
SHA-256 of the local selected-source summary
Local summary SHA-256
266fd242e712c5dbb9884fcaeb0eede2cf0571932b5b33d7a239bba8e35c2541

Provenance and preservation

Additional summaries stored on this page: 1 official-label, 1 RX List, 0 professional, 0 handbook. Empty additional-source groups are not shown. A missing layer is not a no-adjustment recommendation.

Original source
https://globalrph.com/renal/rivaroxaban-xarelto/
Source retrieval
2026-09-05. This is not the source publication or label revision date.
Original source type
globalrph individual
Local text SHA-256
ab36b1216ce744e80d1a1e720cdd32428fae8caf81535f7e5de0dcb196f3d59e
Import versus clinical validation
Source-section locators identify where retained content came from. A source-section identifier does not assert that every numeric statement has been independently corroborated. The local text hash is not a hash of original HTML, an FDA PDF or SPL XML.

The original individual GlobalRPh pages commonly cite NIH/NLM DailyMed and instruct readers to review the applicable package insert for updates. That historical reference is preserved as context; it is not counted as an independently retrieved current label.

Read the full coverage report
Top